Redefining Therapy in Early COPD: RETHINC (H-40614) (H-41604)
Description
Content
This is a 12-week study to asses the efficacy and safety of indacaterol/glycopyrrolate inhaled twice daily in symptomatic current and former smokers with respiratory symptoms despite having a normal spirometry result.
Contact
Phone 1: 713–873–8772
IRB: H-41604
Status:
Active
Created:
